With the ongoing price erosion of its older generation insulin portfolio (in the US), Novo Nordisk sees new growth avenues in GLP-1 products, new generation insulins, and new, but, diabetes-related therapeutic areas – cardiovascular, kidney, obesity and retinopathy. Moreover, International Operations are guided to be a major fulcrum of growth. While strategically these targets have been set in the right direction, realisation of these targets may test the market’s patience.
25 Nov 2019
CMD 2019: right strategy, but execution remains the key
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
CMD 2019: right strategy, but execution remains the key
Novo Nordisk A/S Class B (NNO2:WBO) | 0 0 2.2% | Mkt Cap: 611,927m
- Published:
25 Nov 2019 -
Author:
Surbhit Gupta -
Pages:
4
With the ongoing price erosion of its older generation insulin portfolio (in the US), Novo Nordisk sees new growth avenues in GLP-1 products, new generation insulins, and new, but, diabetes-related therapeutic areas – cardiovascular, kidney, obesity and retinopathy. Moreover, International Operations are guided to be a major fulcrum of growth. While strategically these targets have been set in the right direction, realisation of these targets may test the market’s patience.